Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BeiGene Ltd ( (HK:6160) ) has issued an update.
BeOne Medicines Ltd., a corporation incorporated under the laws of Switzerland, has announced its unaudited financial results for the three and six months ended June 30, 2025. The results, prepared under U.S. GAAP, highlight key business updates and financial guidance for the full year 2025. The announcement underscores the company’s ongoing global expansion efforts and its commitment to bringing transformative medicines to patients worldwide. Stakeholders are advised to exercise caution regarding the financial guidance due to its preliminary nature and the inherent uncertainties.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,745,224
Technical Sentiment Signal: Buy
Current Market Cap: HK$282B
See more insights into 6160 stock on TipRanks’ Stock Analysis page.